BATM Advanced Communications Ltd - Israel-based networking and medical technology company - says it has developed a new test for the rapid and comprehensive diagnosis of tuberculosis. Test takes two hours instead of several days with current methods. Clinical trials to start in second half of this year, fully funded by UN's Stop TB Partnership. Expects sales to begin next year.
Current stock price: 98.40 pence
Year-to-date change: up 5.8%
By Ivan Edwards; ivanedwards@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.


(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...


(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:


(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:


TRADING UPDATES: DX Group And BATM Expect To Beat Market Forecasts


(Sharecast News) - BATM said on Monday that full-year revenues and earnings are set to be ahead of market expectations following stronger-than-expecte...


IN BRIEF: BATM's NFVTime Now Available For Public Cloud Networks


IN BRIEF: BATM Sells NG Soft Subsidiary For GBP25 Million


CORRECT: Pound Rally Ensures FTSE 100 Ends 2020 As Laggard


LONDON MARKET CLOSE: Pound Rally Ensures FTSE 100 Ends 2020 As Laggard


BATM Confirms Effectiveness Of Its Covid Test In Diagnosing New Strain


IN BRIEF: BATM Advanced Ups Interest In Ador Diagnostics